TY - JOUR
T1 - Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of west nile virus infection
AU - Widman, Douglas G.
AU - Ishikawa, Tomohiro
AU - Giavedoni, Luis D.
AU - Hodara, Vida L.
AU - De La Garza, Melissa
AU - Montalbo, Jessica A.
AU - Travassos Da Rosa, Amelia P.
AU - Tesh, Robert B.
AU - Patterson, Jean L.
AU - Carrion, Ricardo
AU - Bourne, Nigel
AU - Mason, Peter W.
PY - 2010/6
Y1 - 2010/6
N2 - West Nile virus (WNV) causes serious neurologic disease, but no licensed vaccines are available to prevent this disease in humans. We have developed RepliVAX WN, a single-cycle flavivirus with an expected safety profile superior to other types of live-attenuated viral vaccines. In this report we describe studies examining RepliVAX WN safety, potency, and efficacy in a non-human primate model of WNV infection. A single immunization of four rhesus macaques with RepliVAX WN was safe and elicited detectable neutralizing antibody titers and IgM and IgG responses, and IgG titers were increased in two animals that received a second immunization. After challenge with WNV, three of four immunized animals were completely protected from viremia, and the remaining animal showed minimal viremia on one day. In contrast, the unvaccinated animal developed viremia that lasted six days. These results demonstrate the efficacy and safety of RepliVAX WN in this primate model of WNV infection.
AB - West Nile virus (WNV) causes serious neurologic disease, but no licensed vaccines are available to prevent this disease in humans. We have developed RepliVAX WN, a single-cycle flavivirus with an expected safety profile superior to other types of live-attenuated viral vaccines. In this report we describe studies examining RepliVAX WN safety, potency, and efficacy in a non-human primate model of WNV infection. A single immunization of four rhesus macaques with RepliVAX WN was safe and elicited detectable neutralizing antibody titers and IgM and IgG responses, and IgG titers were increased in two animals that received a second immunization. After challenge with WNV, three of four immunized animals were completely protected from viremia, and the remaining animal showed minimal viremia on one day. In contrast, the unvaccinated animal developed viremia that lasted six days. These results demonstrate the efficacy and safety of RepliVAX WN in this primate model of WNV infection.
UR - http://www.scopus.com/inward/record.url?scp=77953785380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953785380&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.2010.09-0310
DO - 10.4269/ajtmh.2010.09-0310
M3 - Article
C2 - 20519618
AN - SCOPUS:77953785380
SN - 0002-9637
VL - 82
SP - 1160
EP - 1167
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 6
ER -